WO2017203474A1 - Procédé de préparation d'intermédiaire de sacubutril - Google Patents
Procédé de préparation d'intermédiaire de sacubutril Download PDFInfo
- Publication number
- WO2017203474A1 WO2017203474A1 PCT/IB2017/053105 IB2017053105W WO2017203474A1 WO 2017203474 A1 WO2017203474 A1 WO 2017203474A1 IB 2017053105 W IB2017053105 W IB 2017053105W WO 2017203474 A1 WO2017203474 A1 WO 2017203474A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- protecting group
- preparation
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 150000001875 compounds Chemical class 0.000 claims abstract description 213
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims abstract description 24
- 229960003953 sacubitril Drugs 0.000 claims abstract description 24
- 125000006239 protecting group Chemical group 0.000 claims description 68
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 150000002431 hydrogen Chemical group 0.000 claims description 27
- -1 alkyl chloroformate Chemical compound 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 7
- 239000012279 sodium borohydride Substances 0.000 claims description 7
- 239000004305 biphenyl Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical group CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 3
- TYQICOFAZDVKMK-GOSISDBHSA-N tert-butyl n-[(2r)-1-hydroxy-3-(4-phenylphenyl)propan-2-yl]carbamate Chemical compound C1=CC(C[C@H](CO)NC(=O)OC(C)(C)C)=CC=C1C1=CC=CC=C1 TYQICOFAZDVKMK-GOSISDBHSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 0 CN(C([C@](CO)N(*)*)=O)OC Chemical compound CN(C([C@](CO)N(*)*)=O)OC 0.000 description 13
- ZASXKEGREHRXDL-CAWNUZPDSA-H hexasodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1 ZASXKEGREHRXDL-CAWNUZPDSA-H 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 2
- JXLBBMKZXKVUEI-UHFFFAOYSA-N 1,1'-biphenyl;hydrobromide Chemical compound Br.C1=CC=CC=C1C1=CC=CC=C1 JXLBBMKZXKVUEI-UHFFFAOYSA-N 0.000 description 2
- DJHNFMPUFGYKTR-ZETCQYMHSA-N CC(C)(C)OC(N[C@@H](CO)C(N(C)OC)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CO)C(N(C)OC)=O)=O DJHNFMPUFGYKTR-ZETCQYMHSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- CWMONMPRQNTXIV-LURJTMIESA-N CC(C)(C)OC(N[C@@H](CO)C(NOC)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CO)C(NOC)=O)=O CWMONMPRQNTXIV-LURJTMIESA-N 0.000 description 1
- GDGWFAFNFDEKBH-LBPRGKRZSA-N CC(C)(C)OC(N[C@@H](CO[Si+](C)(C)C(C)(C)C)C(N(C)OC)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CO[Si+](C)(C)C(C)(C)C)C(N(C)OC)=O)=O GDGWFAFNFDEKBH-LBPRGKRZSA-N 0.000 description 1
- JZXHBXSPGBEOBJ-QFIPXVFZSA-N CC(C)(C)OC(N[C@@H](CO[Si+](C)(C)C(C)(C)C)C(c(cc1)ccc1-c1ccccc1)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CO[Si+](C)(C)C(C)(C)C)C(c(cc1)ccc1-c1ccccc1)=O)=O JZXHBXSPGBEOBJ-QFIPXVFZSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- HYGVRONUWGXDLF-UHFFFAOYSA-L magnesium;1,1'-biphenyl;dibromide Chemical compound [Mg+2].[Br-].[Br-].C1=CC=CC=C1C1=CC=CC=C1 HYGVRONUWGXDLF-UHFFFAOYSA-L 0.000 description 1
- JWQLJPBJNSPKSG-UHFFFAOYSA-M magnesium;phenylbenzene;bromide Chemical compound [Mg+2].[Br-].C1=CC=CC=C1C1=CC=[C-]C=C1 JWQLJPBJNSPKSG-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- MBTRMYMICPKJNH-LBPRGKRZSA-N tert-butyl n-[(2s)-3-[tert-butyl(dimethyl)silyl]oxy-1-[methoxy(methyl)amino]-1-oxopropan-2-yl]carbamate Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H](C(=O)N(C)OC)NC(=O)OC(C)(C)C MBTRMYMICPKJNH-LBPRGKRZSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical group [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
- C07D203/20—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carbonic acid, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- the present application relates to a process for the preparation of sacubitril and salt thereof. Specifically, the present application relates to a process for the preparation of an intermediate of sacubitril and salt thereof, tert-butyl (R)-( l -([ l , l '-biphen yl]-4-yl)-3-hydroxypropan-2- yl)carbamate (IA). Specifically, the present application relates to a process for the preparation of sacubitril and salt thereof. The application also relates to a compound of formula (III)
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in rd
- US Patent No. US5217996 A discloses sacubitril and its use in the treatment of cardiovascular disorders.
- US Patent No. US8877938 B2 (hereinafter the US'938 patent) teaches a supra-molecular complex of sacubitril and valsartan. It is known in the literature as LCZ-696 (Tetrahedron Letters 53, 2012, 275-276).
- the chemical name of the supra- molecular complex is trisodium [3-(( l S,3R)- l -biphenyl-4-ylmethyl-3-ethoxycarbonyl-l - butylcarbamoyl)propionate-(S)-3 ' -methyl -2 ' -(pentanoyl ⁇ 2 " -(tetrazol-5-ylate)-biphenyl-4 ylmethyl ⁇ amino)butyrate] hemipentahydrate (CAS # 936623-90-4).
- First aspect of the present application relates to a com ound of formula (III)
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- Second aspect of the present application relates to a process for preparation of compound of formula (III)
- Third aspect of the present application relates to use of compound of formula (III) for the preparation of sacubitril and salt thereof.
- Fourth aspect of the present application relates to use of compound of formula (III) for the preparation of LCZ-696.
- P 2 and P 3 independently, is selected from a group of hydrogen, and any amino protecting group as known in Greene et al., "Protective Groups in Organic Synthesis", 3 rd edition, 1999.
- P 2 and P 3 independently, is selected from a group of hydrogen, and any amino protecting group as known in Greene et al., "Protective Groups in Organic Synthesis", 3 rd edition, 1999.
- Seventh aspect of the present application relates to use of compound of formula (IIIA) for the preparation of sacubitril and salt thereof.
- Eighth aspect of the present application relates to use of compound of formula (IIIA) for the preparation of LCZ-696.
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- Tenth aspect of the present application relates to a process for preparation of compound of formula (IIIB)
- Eleventh aspect of the present application relates to use of compound of formula (IIIB) for the preparation of sacubitril and salt thereof.
- Twelfth aspect of the present application relates to use of compound of formula (IIIB) for the preparation of LCZ-696.
- Fifteenth aspect of the present application relates to use of compound of formula (IIIC) for the preparation of sacubitril and salt thereof.
- Sixteenth aspect of the present application relates to use of compound of formula (IIIC) for the preparation of LCZ-696.
- Seventeenth aspect of the present application relates to a process for the preparation of compound of formula (I)
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- Eighteenth aspect of the present application relates to a process for the preparation of tert- butyl (i?)-(l-([l ,l'-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbamate (IA)
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- Nineteenth aspect of the present application relates to a process for the preparation of sacubitril and salt thereof comprising converting compound of formula (I) or compound of formula (IA), as prepared by the process of the present application, to sacubitril and salt thereof.
- Twentieth aspect of the present application relates to a process for the preparation of LCZ- 696 comprising converting compound of formula (I) or compound of formula (IA), as prepared by the process of the present application, to LCZ-696.
- Twenty first aspect of the present application relates to a process for preparation of compound of formula (IV)
- P 4 is an amino protecting group
- P5 is a hydroxyl protecting group
- R is an Ci-C 6 alkyl
- First aspect of the present application relates to a com ound of formula (III)
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- Second aspect of the present application relates to a process for preparation of compound of formula (III)
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- the suitable hydroxy protecting group of step (a) may be any protecting group known in the art. Specifically, the suitable hydroxy protecting group of step (a) may be any protecting group known in Greene et al., "Protective Groups in Organic Synthesis", 3rd edition, 1999. More specifically, the suitable hydroxy protecting group of step (a) may be a silyl group. Most specifically, the suitable hydroxy protecting group of step (a) may be tert-butyl dimethyl silyl.
- the compound of formula (II) may be treated with suitable hydroxyl protecting group in a solvent including but not limited to polar aprotic solvent such as dimethyl formamide, dimethyl sulfoxide and the like; alcohol solvent such as methanol, ethanol and the like; ether solvent such as tetrahydrofuran, acetone and the like; chlorinated solvent such as dichlorome thane, chloroform and the like; hydrocarbon solvent such as toluene, xylene and the like and mixtures thereof.
- the solvent may be a polar aprotic solvent.
- the compound of formula (II) may be treated with suitable hydroxyl protecting group in presence of a base such as imidazole, morpholine, triethylamine, diisopropyl ethylamine and the like.
- a base such as imidazole, morpholine, triethylamine, diisopropyl ethylamine and the like.
- the base may be imidazole.
- the compound of formula (A) may be treated with 4-biphenyl magnesium halide to provide compound of formula (III).
- the compound of formula (A) may be treated with 4- biphenyl magnesium bromide to provide compound of formula (III).
- the suitable solvent may include but not limited to an alcohol solvent such as methanol, ethanol and the like; ether solvent such as tetrahydrofuran, 1,4-dioxane and the like; ketone solvent such as acetone, methyl ethyl ketone and the like; aromatic hydrocarbon solvent such as toluene, xylene and the like; aliphatic hydrocarbon solvent such as n-hexane, cyclopentane and the like; chlorinated hydrocarbon solvent such as dichlorome thane, chloroform and the like.
- the solvent may be an ether solvent. More specifically, the solvent may be tetrahydrofuran.
- the reaction may be performed for about 15 minutes to about 3 hours at about 0 °C to about boiling point of the solvent. Specifically, the reaction may be performed for about 30 minutes to about 1 hour at about 20 °C to about 30 °C.
- the product, compound of formula (III) may be isolated from the reaction mass by methods known in the art.
- Third aspect of the present application relates to use of compound of formula (III) for the preparation of sacubitril and salt thereof.
- Fourth aspect of the present application relates to use of compound of formula (III) for the preparation of LCZ-696.
- IMA IMA
- P 2 and P 3 independently, is selected from a group of hydrogen, and any amino protecting group as known in Greene et al., "Protective Groups in Organic Synthesis", 3 rd edition, 1999.
- P 2 and P 3 independently, is selected from a group of hydrogen, and any amino protecting group as known in Greene et al., "Protective Groups in Organic Synthesis", 3 rd edition, 1999.
- Seventh aspect of the present application relates to use of compound of formula (IIIA) for the preparation of sacubitril and salt thereof.
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- Tenth aspect of the present application relates to a process for preparation of compound of formula (IIIB)
- Eleventh aspect of the present application relates to use of compound of formula (IIIB) for the preparation of sacubitril and salt thereof.
- Twelfth aspect of the present application relates to use of compound of formula (IIIB) for the preparation of LCZ-696. Thirteenth aspect of the present application relates to a compound of formula (IIIC)
- Fifteenth aspect of the present application relates to use of compound of formula (IIIC) for the preparation of sacubitril and salt thereof.
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- Reduction of compound of formula (III) or compound of formula (HID) in step (d) to provide compound of formula (I) may be performed by catalytic hydrogenation. Specifically, reduction of compound of formula (III) or compound of formula (HID) in step (d) to provide compound of formula (I) may be performed in presence of a heterogeneous catalyst. More specifically, reduction of compound of formula (III) or compound of formula (HID) in step (d) to provide compound of formula (I) may be performed in presence of palladium/charcoal. Optionally, the reduction of compound of formula (III) or compound of formula (HID) in step (d) to provide compound of formula (I) may be performed in presence of an acid.
- the solvent for reduction includes but not limited to an alcohol solvent such as methanol, ethanol and the like; ether solvent such as tetrahydrofuran, 1,4-dioxane and the like; ketone solvent such as acetone, methyl ethyl ketone and the like; aromatic hydrocarbon solvent such as toluene, xylene and the like; an ester solvent such as ethyl ester, n-butyl ester and the like. More specifically, the solvent may be an alcohol solvent. More specifically, the solvent may be methanol.
- the product, compound of formula (I) may be isolated from the reaction mass by a process known in the art.
- One aspect of the present application relates to a compound of formula (IIIF)
- Another aspect of the present application relates to isolation of compound of formula (IIIF) from the reaction mixture and optional purification by a process known in the art, e.g. crystallization and then further reduction of compound of formula (IIIF) to provide compound of formula (I).
- the compound of formula (IIIF) may be directly reduced, without isolation, to provide compound of formula (I), wherein compound of formula (IIIF) may be produced as an intermediate.
- Eighteenth aspect of the present application relates to a process for the preparation of tert- butyl (i?)-(l-([l ,l'-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbamate (IA)
- Pi is selected from a group of hydrogen, and any hydroxy protecting group as known in
- One aspect of the present application relates to a com ound of formula (IIIG)
- Another aspect of the present application relates to isolation of compound of formula (IIIG) from the reaction mixture and optional purification by a process known in the art, e.g. crystallization and then further reduction of compound of formula (IIIG) to provide compound of formula (IA).
- the compound of formula (IIIG) may be directly reduced, without isolation, to provide compound of formula (IA), wherein compound of formula (IIIG) may be produced as an intermediate.
- the compound of formula (I) or compound of formula (IA) may be converted to sacubitril and salt thereof by a process known in the art. Specifically, the compound of formula (I) or compound of formula (IA) may be converted to sacubitril by a process as known in the PCT application, WO2008/031567A1. Sacubitril and salt thereof, as produced by the process of the present application, may be converted to LCZ-696 as known in the US'938 patent.
- Twenty first aspect of the present application relates to a process for preparation of compound of formula (IV)
- P 4 is an amino protecting group
- P5 is a hydroxyl protecting group
- R is an Ci-C 6 alkyl
- One specific aspect of the present application relates to a process for the preparation of compound of formula (IVA)
- TBS is tert-butyl dimethylsilyl and Boc is tert-butyloxycarbonyl.
- Step (a) may be performed in a suitable solvent including but not limited to alcohol solvent such as methanol, ethanol and the like; ether solvent such as tetrahydrofuran, 1,4-dioxane and the like; ketone solvent such as acetone, methyl ethyl ketone and the like; aromatic hydrocarbon solvent such as toluene, xylene and the like; an ester solvent such as ethyl ester, n-butyl ester and the like.
- the solvent may be an ether solvent. More specifically, the solvent may be tetrahydrofuran.
- Step (a) may be performed from about 0 °C to about boiling point of the solvent for about 15 minutes to about 5 hours.
- step (a) may be performed from about 5 °C to about 10 °C for about 30 minutes to about 2 hours.
- the product, compound of formula (VI), may be isolated by any known methods in the art. Alternatively, the product may be carried forward to the next step as such.
- Step (al) may be performed in a suitable solvent including but not limited to ether solvent such as tetrahydrofuran, 1,4-dioxane and the like; ketone solvent such as acetone, methyl ethyl ketone and the like; aromatic hydrocarbon solvent such as toluene, xylene and the like; an ester solvent such as ethyl ester, n-butyl ester and the like.
- the solvent may be an ester solvent. More specifically, the solvent may be ethyl acetate.
- Step (al) may be performed from about 0 °C to about boiling point of the solvent for about 15 minutes to about 15 hours.
- step (al) may be performed from about 0 °C to about 40 °C for about 1 hour to about 8 hours.
- the reaction of compound of formula (V) and N-hydroxysuccinimide may be performed in presence of N,N'-dicyclohexylcarbodiimide.
- the product, compound of formula (VIII) may be isolated by any known methods in the art. Alternatively, the product may be carried forward to the next step as such.
- Step (b) may be performed in a suitable solvent including but not limited to alcohol solvent such as methanol, ethanol and the like; ether solvent such as tetrahydrofuran, 1 ,4-dioxane and the like; ketone solvent such as acetone, methyl ethyl ketone and the like; aromatic hydrocarbon solvent such as toluene, xylene and the like; an ester solvent such as ethyl ester, n-butyl ester and the like; mixtures thereof.
- step (b) may be performed in a mixture of an alcohol solvent and an ether solvent. More specifically, step (b) may be performed in a mixture of methanol and tetrahydrofuran.
- step (b) may be performed in a mixture of an ester solvent and an ether solvent.
- step (b) may be performed in a mixture of ethyl acetate and tetrahydrofuran.
- Step (b) may be performed from about 0 °C to about boiling point of the solvent for about 1 hour to about 25 hours. Specifically, step (b) may be performed from about 20 °C to about 50 °C for about 5 hours to about 15 hours. Alternatively, step (b) may be performed at about 0 °C to about 20 °C for about 15 minutes to about 2 hours.
- the product, compound of formula (VII) may be isolated by any known methods in the art. Alternatively, the product may be carried forward to the next step as such.
- the cyclization of compound of formula (VII) to provide compound of formula (IV) in step (c) may be carried out by a process as known in the art. Specifically, the step (c) may be carried out by a process as known in Tetrahedron Letters, 1998, 39(51 ), 9389.
- the compound of formula (V) may be prepared by a process known in the art. Specifically, the compound of formula (V) may be prepared by a process as known in Tetrahedron Letters, 1984, 25(9), 91 1.
- the compound of formula (IV) may be converted into compound of formula (I) by a process known in the art. Specifically, the compound of formula (IVA) may be converted into compound of formula (IA) by a process known in CN105237560A.
- N-Boc-L-Serine (30 g) in dichloromethane (600 mL)
- N-methyl morpholine (15.53 g)
- N,0-dimethylhydroxylammonium chloride (15.69 g)
- N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride 28.9 g
- the reaction mass was stirred further for 2 hours at about 10-28 °C.
- the reaction mass was quenched by 1M hydrochloric acid (150 mL).
- the organic layer was separated and the aqueous layer was extracted with dichloromethane (2 x 300 mL).
- the combined organic layer was washed with sodium bicarbonate solution (10 %, 150 mL), distilled under vacuum to provide solid desired compound.
- Example 3 Preparation of tert-butyl (5)-(3,8,8,9,9-pentamethyl-4-oxo-2,7-dioxa-3-aza-8- siladecan-5-yl)carbamate (D) To a solution of (5)-tert-butyl-(3 -hydroxy- l -(metho xy(methyl)amino)-l -oxopropan -2- yl)carbamate (IIA) (10 g) in dimethyl formamide (80 mL), imidazole (5.48 g) was added at 0 °C and stirred for 5 minutes.
- DIIA imidazole
- Example 6 Sodium borohydride (1.18 g) was added to the filtrate of Example 6 slowly and the reaction mass was allowed to heat up to 40-45 °C. Methanol (10 mL) was added to the reaction mass. The reaction mass was stirred for about 15 hours and then quenched by the addition of ammonium chloride solution (2 g in 20 mL water). The reaction mass was extracted with ethyl acetate (150 mL), the organic layer was washed with brine (40 mL) and dried over sodium sulfate. The organic layer was distilled under vacuum to provide crude desired compound, which was purified by column chromatography over silica gel using 20% ethyl actetate/n-hexane as eluant. Yield: 3.3 g
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne un procédé de préparation de tert-butyl (R)-(1-([1,1'-biphényl]-4-yl)-3-hydroxypropan-2-yl) carbamate (IA). Le composé de formule (IA) peut être utilisé en tant qu'intermédiaire pour la préparation de sacubitril. (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641018295 | 2016-05-27 | ||
IN201641018295 | 2016-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017203474A1 true WO2017203474A1 (fr) | 2017-11-30 |
Family
ID=60412691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/053105 WO2017203474A1 (fr) | 2016-05-27 | 2017-05-26 | Procédé de préparation d'intermédiaire de sacubutril |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017203474A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190256454A1 (en) * | 2016-07-05 | 2019-08-22 | Novartis Ag | New process for early sacubitril intermediates |
WO2020127780A1 (fr) | 2018-12-20 | 2020-06-25 | Bayer Aktiengesellschaft | Hétérocyclyl-pyridazine utilisée en tant que composés fongicides |
WO2021245083A1 (fr) | 2020-06-04 | 2021-12-09 | Bayer Aktiengesellschaft | Hétérocyclyl pyridines en tant que nouveaux fongicides |
WO2021245087A1 (fr) | 2020-06-04 | 2021-12-09 | Bayer Aktiengesellschaft | Hétérocyclyl pyrimidines et triazines en tant que nouveaux fongicides |
WO2021249995A1 (fr) | 2020-06-10 | 2021-12-16 | Bayer Aktiengesellschaft | Hétérocycles à substitution azabicyclyle utilisés comme fongicides |
WO2021255070A1 (fr) | 2020-06-18 | 2021-12-23 | Bayer Aktiengesellschaft | Combinaisons de composés actifs |
WO2021255071A1 (fr) | 2020-06-18 | 2021-12-23 | Bayer Aktiengesellschaft | Dérivés de 3-(pyridazin-4-yl)-5,6-dihydro-4h-1,2,4-oxadiazine utilisés comme fongicides pour la protection des cultures |
CN115745841A (zh) * | 2021-09-03 | 2023-03-07 | 凯特立斯(深圳)科技有限公司 | 一种沙库必曲中间体的制备方法 |
WO2023099445A1 (fr) | 2021-11-30 | 2023-06-08 | Bayer Aktiengesellschaft | Bis(hétéro)aryl thioéther oxadiazines utilisées en tant que composés fongicides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015037460A1 (fr) * | 2013-09-10 | 2015-03-19 | 住友化学株式会社 | PROCÉDÉ DE PRODUCTION DE 3-(BIPHÉNYLE-4-YL)-2-[(t-BUTOXYCARBONYL)AMINO]PROPAN-1-OL OPTIQUEMENT ACTIF |
US20150210632A1 (en) * | 2012-08-31 | 2015-07-30 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd | New process |
CN105237560A (zh) * | 2015-10-15 | 2016-01-13 | 上海博氏医药科技有限公司 | 一种lzc696中间体及其合成方法 |
-
2017
- 2017-05-26 WO PCT/IB2017/053105 patent/WO2017203474A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150210632A1 (en) * | 2012-08-31 | 2015-07-30 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd | New process |
WO2015037460A1 (fr) * | 2013-09-10 | 2015-03-19 | 住友化学株式会社 | PROCÉDÉ DE PRODUCTION DE 3-(BIPHÉNYLE-4-YL)-2-[(t-BUTOXYCARBONYL)AMINO]PROPAN-1-OL OPTIQUEMENT ACTIF |
CN105237560A (zh) * | 2015-10-15 | 2016-01-13 | 上海博氏医药科技有限公司 | 一种lzc696中间体及其合成方法 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190256454A1 (en) * | 2016-07-05 | 2019-08-22 | Novartis Ag | New process for early sacubitril intermediates |
WO2020127780A1 (fr) | 2018-12-20 | 2020-06-25 | Bayer Aktiengesellschaft | Hétérocyclyl-pyridazine utilisée en tant que composés fongicides |
WO2021245083A1 (fr) | 2020-06-04 | 2021-12-09 | Bayer Aktiengesellschaft | Hétérocyclyl pyridines en tant que nouveaux fongicides |
WO2021245087A1 (fr) | 2020-06-04 | 2021-12-09 | Bayer Aktiengesellschaft | Hétérocyclyl pyrimidines et triazines en tant que nouveaux fongicides |
WO2021249995A1 (fr) | 2020-06-10 | 2021-12-16 | Bayer Aktiengesellschaft | Hétérocycles à substitution azabicyclyle utilisés comme fongicides |
WO2021255070A1 (fr) | 2020-06-18 | 2021-12-23 | Bayer Aktiengesellschaft | Combinaisons de composés actifs |
WO2021255071A1 (fr) | 2020-06-18 | 2021-12-23 | Bayer Aktiengesellschaft | Dérivés de 3-(pyridazin-4-yl)-5,6-dihydro-4h-1,2,4-oxadiazine utilisés comme fongicides pour la protection des cultures |
CN115745841A (zh) * | 2021-09-03 | 2023-03-07 | 凯特立斯(深圳)科技有限公司 | 一种沙库必曲中间体的制备方法 |
WO2023029235A1 (fr) * | 2021-09-03 | 2023-03-09 | 凯特立斯(深圳)科技有限公司 | Procédé de préparation d'un intermédiaire de sacubitril |
CN115745841B (zh) * | 2021-09-03 | 2024-04-16 | 凯特立斯(深圳)科技有限公司 | 一种沙库必曲中间体的制备方法 |
WO2023099445A1 (fr) | 2021-11-30 | 2023-06-08 | Bayer Aktiengesellschaft | Bis(hétéro)aryl thioéther oxadiazines utilisées en tant que composés fongicides |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017203474A1 (fr) | Procédé de préparation d'intermédiaire de sacubutril | |
CN113754665B (zh) | 一种核苷类化合物的制备方法 | |
EP2632889B1 (fr) | Composés intermédiaires et procédé de préparation de fingolimod | |
WO2009141837A2 (fr) | Procédé de préparation d'un composé de posaconazole et de produits intermédiaires associés | |
EP2883858B1 (fr) | Procédé de fabrication de dérivé d'hexahydrofurofuranol | |
EP2768806A1 (fr) | Procédé de préparation de silodosine | |
Ji et al. | Diastereospecific epoxidation and highly regioselective ring-opening of (+)-valienamine: practical synthesis of (+)-valiolamine | |
WO2010015107A1 (fr) | Synthèse stéréosélective de valiolamine | |
WO2015145467A1 (fr) | Procédé amélioré de préparation de vildagliptine | |
EP2807143A2 (fr) | Procédé pour la préparation de fingolimod | |
Hamada et al. | Insect pheromone synthesis using Mn-salen catalyzed asymmetric epoxidation as a key step | |
KR20120039344A (ko) | 엔독시펜의 신규한 제조 방법 | |
WO2012004811A1 (fr) | Procédé pour la préparation de dérivé d'indole substitué en position 5 | |
KR100714197B1 (ko) | 보글리보스의 제조방법 | |
Dondoni et al. | Regio-and stereoselective conjugate addition of nitrogen nucleophiles to 2-alkenyl n-methylthiazolium iodides. synthesis of d-3-epi-daunosamine and some lincosamine analogues | |
US20090281301A1 (en) | Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate | |
EP3344602A1 (fr) | Procédé amélioré de préparation de paroxétine et de son intermédiaire | |
JP5704763B2 (ja) | トランス−4−アミノシクロペンタ−2−エン−1−カルボン酸誘導体の製造 | |
KR100982720B1 (ko) | 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트의 생산을 위한 중간체로서의 2-아미노말론아미드의제조방법 | |
EP1651627A2 (fr) | Procede de preparation d'oxetan-2-ones | |
WO2009137691A2 (fr) | Synthèse de 1,3-diol par fonctionnalisation contrôlée de c-h avec radicaux | |
JP2007262089A (ja) | アミノ置換カルボ糖の製造方法 | |
JPH0791264B2 (ja) | N−(2−アミノ−3−ヒドロキシベンゾイル)−l−プロリナ−ルアセタ−ルおよびその製造方法 | |
JP3144920B2 (ja) | α−アシルアミノケトン誘導体、その製造方法及びその利用 | |
JP3144921B2 (ja) | ベンジルエステル誘導体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17802300 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17802300 Country of ref document: EP Kind code of ref document: A1 |